X
CAR-Ts – a new weapon in the fight against cancer
https://pharmaphorum.com/views-and-analysis/car-ts-a-new-weapon-in-the-fight-against-cancer/
Deep Dive
Non-adherence: pharma’s final financial frontier
No other industry would tolerate avoidable annual losses of $637 billion, but that’s exactly what pharma is doing by not investing in adherence. Now is the time to start recovering that revenue.
Uncovering patient-centred insights
There are good reasons why patient centricity has become such a well-used term within the pharmaceutical industry. But, says Kantar Health’s Linda VerPlanck, the research approaches underpinning it must be able to deliver transformational insights that can, in turn, improve real-world outcomes.
Five practical steps to patient centricity
How can pharma marketers put patients at the centre of product strategy and help improve their conditions?
Interview: David Mitchell of Patients For Affordable Drugs
In the latest edition of our Deep Dive magazine – Deep Dive: Patient Centricity II – David Mitchell, President of Patients For Affordable Drugs, speaks to pharmaphorum’s Andrew McConaghie about why the organisation was set up and why its campaigning work is so important for patients.
